References
- Wadler S, Scwartz E L, Goldman M, et al. Fluorouracil and recombinant alfa 2-a interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1769–1775
- Khöne-Wömpner C H, Schmoll H J, Harstrick A, Rustum Y M. Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinicals trials. Semin Oncol 1992; 19(Suppl 3)105–125
- Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903
- Kemeny N, Younes A, Seifert K, et al. Interferon alfa-2a and fluorouracil for advanced colorectal carcinoma: Assessment of activity and toxicity. Cancer 1990; 66: 2470–2475
- Wadler S, Schmoll H J. Roundtable discussion: Second International Workshop on Gastrointestinal Cancer, Recent Development in Biomodulation. Semin Oncol 1992; 19(Suppl 3)234–235
- Pazdur Moore D F, Bready B. Modulation of fluorouracil with recombinant alfa interferon: M.D. Anderson clinical trial. Semin Oncol 1992; 19(Suppl 3)176–179
- Wadler S, Lemberkg B, Atkins M, et al. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1991; 9: 1806–1810